The typical first-line treatment is surgical removal of the tumor, but if hypersecretion of GH and IGF-I continues, then symptoms are commonly managed with pharmacological treatments, such as somatostatin receptor ligands (SRL) (e.g., octreotide, lanreotide) or other medications that either reduce GH hormone secretion or antagonize the GH receptor [1, 7]. The gene discussed is GH1; the disease is neoplasm.